Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 25 2024
0mins
Source: NASDAQ.COM
Company Performance: Biogen Inc. has significantly underperformed the market, with a 31.7% decline over the past year compared to a nearly 31% rise in the S&P 500; its recent Q3 results showed a 6.4% drop in adjusted EPS and a 2.5% decrease in revenue year-over-year.
Analyst Ratings and Future Outlook: Despite a mixed earnings surprise history, analysts maintain a "Moderate Buy" consensus on BIIB stock, with price targets suggesting potential upside ranging from 31.1% to 116.6% from current levels.
Analyst Views on IBRN
Wall Street analysts forecast IBRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBRN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 32.790
Low
Averages
High
Current: 32.790
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
